Kleenex Maker Kimberly-Clark Acquires Kenvue in £37bn Mega-Deal
In one of the largest acquisitions of the year, consumer goods giant Kimberly-Clark has agreed to purchase rival Kenvue for £37 billion. The deal brings together iconic brands like Kleenex and Huggies with Kenvue’s portfolio including Listerine, Tylenol, Aveeno, and Neutrogena.
Key Takeaways
- Kimberly-Clark acquires Kenvue in £37 billion deal
- Kenvue shares surged 15%, Kimberly-Clark fell 13%
- Combined company projected to generate £24 billion annual revenue
- Deal comes amid controversy over Tylenol safety claims
Market Reaction and Concerns
The acquisition announcement sent shockwaves through Wall Street, with Kenvue shares jumping 15% while Kimberly-Clark stock dropped 13%. The market reaction indicates investor concerns about the timing and valuation of the deal.
Jay Woods at Freedom Capital Markets noted the reaction suggests some investors believe Kimberly-Clark ‘may be buying damaged goods’.
Political Controversy Surrounding Tylenol
The deal arrives during ongoing tensions between Kenvue and the White House. Former President Donald Trump has made unproven claims that Tylenol use during pregnancy can cause autism in children, leading to declining US sales of the painkiller after Trump urged pregnant women to stop taking it in September.
Danni Hewson from broker AJ Bell commented: ‘Kenvue comes with some baggage, not least a rocky relationship with the White House.’
Company Backgrounds
Kenvue, which was spun out of Johnson & Johnson in 2023, has experienced a challenging year with shares down by a third before yesterday’s rally. The combined entity will unite Kimberly-Clark’s Andrex with Kenvue’s extensive brand portfolio including the Johnson’s Baby range.
Despite the controversies, Kimberly-Clark projects the merged company will achieve annual revenues of £24 billion, creating a consumer healthcare and personal care powerhouse.
